Company Overview
About Nabla Bio
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
Business Model & Competitive Advantage
Nabla Bio's generative protein design platform creates novel antibody architectures specifically optimized for binding to multipass membrane proteins — using deep learning to design proteins that can access and bind the exposed loops and domains of these structurally complex targets that conventional antibody discovery methods fail to address reliably. GPCRs alone are targets of approximately 34% of all FDA-approved drugs, but mainly through small molecules; antibodies offer advantages including higher specificity and longer half-life that small molecules can't achieve.
Competitive Landscape 2025–2026
In 2025, Nabla Bio competes in the AI drug discovery and protein design market with Recursion Pharmaceuticals (RXRX), AbSci (AI antibody design), and Insilico Medicine for AI-powered drug target and antibody discovery, and with traditional antibody discovery companies (AbCellera, Sorrento, Regeneron's VelociSuite) for GPCRs and ion channel antibody programs. The $550M+ partnership revenue from AstraZeneca, BMS, and Takeda validates the platform's commercial appeal to major pharmaceutical companies that need access to the multipass membrane protein antibody capabilities Nabla Bio has built. Radical Ventures' Series A lead reflects deep AI research investment thesis. The 2025 strategy focuses on advancing partnership programs toward the clinic, identifying and developing proprietary pipeline programs in GPCR oncology and neurological disease indications, and expanding the computational protein design platform to additional target classes.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Nabla Bio is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Nabla Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nabla Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nabla Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nabla Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →